This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Abdollahi, T. Articles by Litwack, G. Search for Related Content PubMed PubMed Citation Articles by Abdollahi, T. Articles by Litwack, G.

Identification of Interleukin 8 as an Inhibitor of Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in the Ovarian Carcinoma Cell Line OVCAR3¹

Department of Biochemistry and Molecular Pharmacology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107 [T. A., N. M. R., G. W.], and Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania [A. A.]

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is known to trigger apoptosis in many malignant cells. Whereas cancer cells are responsive to TRAIL-induced cell death when used alone or in combination with other agents, normal cells are known to be relatively less sensitive to the ligand, making it a desirable therapeutic compound to target a variety of cancers. TRAIL induces apoptosis through its interaction with its two proapoptotic death receptors (DRs), DR4 and DR5. In addition, it may also bind the decoy receptors (DcRs), DcR1 and DcR2, which lack an intracellular signaling domain, thus negatively regulating TRAIL-induced apoptosis. Previously, it has been shown that interleukin (IL)-8 is elevated in the ascites of patients with ovarian cancer. Therefore, we examined the role that IL-8 may play in modulating sensitivity to TRAIL-mediated apoptosis. We treated the TRAIL-sensitive cell line OVCAR3 with TRAIL over a period of time with or without pretreatment with IL-8. Here we show the novel findings that IL-8 blocks TRAIL-induced cell death and was able to turn the TRAIL-sensitive cell line into a TRAIL-resistant one. We hypothesized that decreased expression of DRs DR4 and DR5 may contribute to TRAIL resistance. Both reverse transcription-PCR and flow cytometry revealed a decrease in DR4 expression after pretreatment of OVCAR3 cells with IL-8. We have also shown that TRAIL was able to induce caspase-8 cleavage in these cells, whereas pretreatment with IL-8 blocked this caspase cleavage. Through array analysis and confirmation with other techniques, we have determined that IL-8 regulates the expression of a member of the mitogen-activated protein kinase superfamily, p38. These findings provide important insights into the modulation of apoptosis by TRAIL and IL-8 in ovarian cancer. The data suggest a potentially important role of IL-8 in protecting ovarian cancer cells from TRAIL-mediated apoptosis and signify a new potential chemotherapeutic target to augment TRAIL therapy.

This article has been cited by other articles:

				M. J. Szczepanski, M. Czystowska, M. Szajnik, M. Harasymczuk, M. Boyiadzis, A. Kruk-Zagajewska, W. Szyfter, J. Zeromski, and T. L. Whiteside Triggering of Toll-like Receptor 4 Expressed on Human Head and Neck Squamous Cell Carcinoma Promotes Tumor Development and Protects the Tumor from Immune Attack Cancer Res., April 1, 2009; 69(7): 3105 - 3113. [Abstract] [Full Text] [PDF]

				C. Wilson, C. Purcell, A. Seaton, O. Oladipo, P. J. Maxwell, J. M. O'Sullivan, R. H. Wilson, P. G. Johnston, and D. J. J. Waugh Chemotherapy-Induced CXC-Chemokine/CXC-Chemokine Receptor Signaling in Metastatic Prostate Cancer Cells Confers Resistance to Oxaliplatin through Potentiation of Nuclear Factor-{kappa}B Transcription and Evasion of Apoptosis J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 746 - 759. [Abstract] [Full Text] [PDF]

				C. Wilson, T. Wilson, P. G. Johnston, D. B. Longley, and D. J.J. Waugh Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells Mol. Cancer Ther., September 1, 2008; 7(9): 2649 - 2661. [Abstract] [Full Text] [PDF]

				L. E. Perez, N. Parquet, K. Shain, R. Nimmanapalli, M. Alsina, C. Anasetti, and W. Dalton Bone Marrow Stroma Confers Resistance to Apo2 Ligand/TRAIL in Multiple Myeloma in Part by Regulating c-FLIP J. Immunol., February 1, 2008; 180(3): 1545 - 1555. [Abstract] [Full Text] [PDF]

				R. V. Warke, K. J. Martin, K. Giaya, S. K. Shaw, A. L. Rothman, and I. Bosch TRAIL Is a Novel Antiviral Protein against Dengue Virus J. Virol., January 1, 2008; 82(1): 555 - 564. [Abstract] [Full Text] [PDF]

				X. Qi, J. Tang, M. Loesch, N. Pohl, S. Alkan, and G. Chen p38{gamma} Mitogen-Activated Protein Kinase Integrates Signaling Crosstalk between Ras and Estrogen Receptor to Increase Breast Cancer Invasion. Cancer Res., August 1, 2006; 66(15): 7540 - 7547. [Abstract] [Full Text] [PDF]

				F Gilli, F Marnetto, M Caldano, A Sala, S Malucchi, M Capobianco, and A Bertolotto Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1 Multiple Sclerosis, February 1, 2006; 12(1): 47 - 57. [Abstract] [PDF]

				M. Moscova, D. J. Marsh, and R. C. Baxter Protein Chip Discovery of Secreted Proteins Regulated by the Phosphatidylinositol 3-Kinase Pathway in Ovarian Cancer Cell Lines Cancer Res., February 1, 2006; 66(3): 1376 - 1383. [Abstract] [Full Text] [PDF]

				J. Tang, X. Qi, D. Mercola, J. Han, and G. Chen Essential Role of p38{gamma} in K-Ras Transformation Independent of Phosphorylation J. Biol. Chem., June 24, 2005; 280(25): 23910 - 23917. [Abstract] [Full Text] [PDF]

				P. Horak, D. Pils, G. Haller, I. Pribill, M. Roessler, S. Tomek, R. Horvat, R. Zeillinger, C. Zielinski, and M. Krainer Contribution of Epigenetic Silencing of Tumor Necrosis Factor-Related Apoptosis Inducing Ligand Receptor 1 (DR4) to TRAIL Resistance and Ovarian Cancer Mol. Cancer Res., June 1, 2005; 3(6): 335 - 343. [Abstract] [Full Text] [PDF]

				C. J. Sweeney, S. Mehrotra, M. R. Sadaria, S. Kumar, N. H. Shortle, Y. Roman, C. Sheridan, R. A. Campbell, D. J. Murry, S. Badve, et al. The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer Mol. Cancer Ther., June 1, 2005; 4(6): 1004 - 1012. [Abstract] [Full Text] [PDF]

				A.-M. Hui, W. Zhang, W. Chen, D. Xi, B. Purow, G. C. Friedman, and H. A. Fine Agents with Selective Estrogen Receptor (ER) Modulator Activity Induce Apoptosis In vitro and In vivo in ER-Negative Glioma Cells Cancer Res., December 15, 2004; 64(24): 9115 - 9123. [Abstract] [Full Text] [PDF]